Abstract: The present disclosure discloses a method for preparing lipase with high ester synthesis activity by using surfactant, belonging to the field of enzyme engineering. The present disclosure provides a method for obtaining a lipase with high ester synthesis activity by adding different surfactants with different concentrations in a lipase aqueous solution and then freeze-drying. The lipase meets the requirement in non-aqueous catalysis. Mixing a variety of lipase with no ester synthesis activity or low activity at suitable concentration and an appropriate concentration of the surfactant in the solution can produces lipases with significantly improved ester synthesis activity, meanwhile changing the hydrolytic activity of the lipase. Increased ester synthesis activity makes lipase more suitable for industrial applications.

Abstract: The present invention relates to a polypeptide having lipase activity wherein the polypeptide, which, when aligned with a polypeptide according to SEQ ID NO: 1, comprises at least one amino acid substitution resulting in Ser (S), Ala (A) or Leu (L) at position 246, Trp (W) at position 307, Leu (L) at position 345, Ile (I) at position 365, and/or Phe (F) at position 534, wherein the position is defined with reference to SEQ ID NO: 1, wherein Ala(A) at position 1 in SEQ ID NO: 1 is counted as number 1 and a method for preparing the polypeptide. The present invention further relates to a process for preparing a food product wherein a polypeptide according to the present invention is used.

Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Abstract: The present invention relates to genome editing by the mean of Cas nucleases. The inventors found that the expression of Cas nucleases may be finely controlled by the use of regulatory elements comprising a minimal promoter and at least one amino acid response element (AARE) nucleic acid, which are responsive to a diet deficient in at least one essential amino acid, or tunicamycin. For example, a FLAG-Cas9-GFP fusion and a Cas9-FLAG-RFP fusion could be expressed in 293 T cells. In addition, in the presence of a donor plasmid bearing a puromycin resistant gene, integration of the said puromycin resistant gene may be performed at the site of the safe harbour locus AASV1 on the genome of 293 T cells.

Abstract: The present invention relates to isolated polypeptides having cellulolytic activity or hemicellulolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to thermostable pullulanases useful for industrial and scientific purposes. The present invention provides methods for producing the modified pullulanase, enzymatic compositions comprising the modified pullulanase, and methods for use of the enzymatic compositions.

Abstract: The present disclosure discloses methods for high-yield fermentation of recombinant proline aminopeptidase and preparation of debittered rice peptide, belonging to the fields of fermentation technology, enzyme preparation and food additives. The present disclosure utilizes fermentation kinetic analysis to determine the high-yield fermentation method of proline aminopeptidase by recombinant Bacillus subtilis, and improve the yield of proline aminopeptidase to reach 174.8 U/mL. Proline aminopeptidase cooperates with alkaline protease and leucine aminopeptidase to hydrolyze rice protein. The free amino acid content is 27.3 times the unhydrolyzed free amino acid content, and the small peptide content below 180 Da in hydrolysate reaches 44.70%. The exposed N-terminal proline residue is fully hydrolyzed, and the free proline content is 1,064.3 times that of the unhydrolyzed free proline content, which increases the degree of rice protein hydrolysis.

Abstract: In various embodiments, the invention provides subtiligase variants that recognize an N-terminus of a protein or peptide substrate that is different than the N-terminus that is recognized by the corresponding wild-type subtiligase. Also provided are methods and kits for using such subtiligase variants to site-specifically ligate a synthetic molecule comprising a peptide ester to a protein or peptide substrate of interest.

Abstract: A polypeptide having an amino acid sequence corresponding to a binding domain of a botulinum toxin is described. The polypeptide modulates expression of genes involved in, for example, collagen production and extra cellular matrix organization, and finds use, therefore in treating or reducing the occurrence of a disease such as a disease of the ECM, a connective or epithelial tissue disease, an endothelial disease or a fibrotic disease, e.g., a fibrotic disease of the ECM, connective tissue, or endothelium. Nucleic acids encoding the polypeptide, as well as vectors, host cells, and systems comprising the nucleic acids, are further described.

Abstract: The present disclosure relates to serine proteases cloned from Bacillus spp., and variants thereof. Compositions containing the serine proteases are suitable for use in cleaning fabrics and hard surfaces, as well as in a variety of industrial applications.

Abstract: Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury.

Abstract: The present disclosure discloses a thermophilic L-asparaginase mutant and screening and fermentation methods thereof, and belongs to the field of gene engineering, enzyme engineering and fermentation engineering. In bacillus subtilis 168, a Pyrococcus yayanosii CH1-derived L-asparaginase encoding gene is used as a template, and a mutation library is constructed by an error-prone PCR (epPCR) technology. A mutant strain with improved specific enzyme activity is screened through a high-flux screening method of synchronous cell disruption and enzyme activity measurement. Mutated residues included in a positive mutant are analyzed to construct a composite mutant strain S17G/A90S/R156S/K272A with improved specific enzyme activity and specific enzyme activity of 3108 U/mg. An expression quantity of the composite mutant strain in the bacillus subtilis 168 is increased through measures of a strong promoter P43 and RBS optimization.

Abstract: The present invention relates to xanthan lyase variants and methods for obtaining xanthan lyase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The invention is in the field of biotechnology and involves recombinant DNA technology. It provides means and methods for obtaining an insoluble active fusion protein comprising xylose isomerase activity. More in particular, the invention relates to a method for obtaining active insoluble xylose isomerase, comprising the expression in a host organism of a recombinant gene encoding a fusion protein comprising a xylose isomerase in combination with a PPIase, thereby obtaining the active insoluble xylose isomerase. It also provides recombinant fusion proteins comprising xylose isomerase activity as well as their use in converting xylose to xylulose and glucose to fructose.

Abstract: The present invention is based on the advantageous use of single-stranded oligonucleotides in the in vivo (within a cell) assembly of double-stranded oligonucleotides into a single double-stranded nucleic acid construct. The present invention relates to the use of at least a first and a second single-stranded oligonucleotide in the assembly within a cell of at least two double-stranded nucleic acid molecules into a single double-stranded nucleic acid construct of pre-determined sequence, wherein the first and second single-stranded oligonucleotide are essentially complementary to each other.

Abstract: The present disclosure provides CRISPR/Cas9 ribonucleoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (tracrRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.

Abstract: Methods of selecting an aptamer that specifically binds to a target molecule complexed with a derivatization agent. Also disclosed are specific aptamers and methods of use thereof.

Abstract: In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.

Abstract: The present invention relates to methods for improving at least one property of a microorganism host cell by repressing the expression of one or more genome target sequence of interest by CRISPR-inhibition as well as the resulting host cells and methods of production emplying said host cells.

Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL4 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL4 gene in a cell by genome editing.

Abstract: The present disclosure relates to single guide RNA (sgRNA), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associate protein 9 (Cas9) system, and methods of use thereof for preventing, ameliorating or treating corneal dystrophies.

Abstract: An exosome secretion inhibitor containing a substance suppressing expression of NAPG, HINT3 or GXYLT1 gene, or a substance suppressing activity of NAPG, HINT3 or GXYLT1 protein. It is possible to suppress secretion of exosome, thereby making it possible to suppress proliferation or metastasis of cancer cells, so that the substance suppressing expression of the gene or activity of the protein can be used as an active ingredient of a pharmaceutical composition suitably used in treatment of cancer or suppression of cancer metastasis, and also the substance can provide a carcinostatic agent having a new action mechanism which specifically suppresses expression of the gene or activity of the protein.

Abstract: MicroRNAs can be used to decrease expression of apolipoprotein B (apoB), increase expression of apolipoprotein A (apoA), and decrease expression of NCOR1. Use of these microRNAs can simultaneously reduce LDL and increase HDL in circulation and have applications in prevention and treatment of atherosclerosis, hyperlipidemia, and cardiovascular disease as well as other disorders associated with high apoB and/or low apoAI levels.

Abstract: The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided.

Abstract: Provided herein are compositions that include a metal nanoparticle functionalized with a miRNA and a targeting molecule. The compositions may be used to prevent or reduce the rate of metastasis of cancer cells. The compositions also may include a drug, such as a chemotherapeutic agent. The compositions also may include a hydrogel in which the metal nanoparticles are dispersed. Methods of miRNA and/or drug delivery and kits also are provided.

Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.

Abstract: Provided herein are synthetic nucleic acid molecules and methods of using such synthetic nucleic acid molecules for strong repression of target gene expression. In particular, provided herein are methods for altering expression of a protein in a cell, where the method comprises introducing into a cell a protein coding sequence operably linked to a near-threshold translational repressor having first and second trigger recognition sequences that are fully or partially complementary to a repressing trigger RNA; and introducing into a cell the repressing trigger RNA.

Abstract: The present invention relates to a novel promoter, a vector comprising the promoter, a microorganism comprising the promoter or the vector, and a method for producing a target product using the microorganism.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease. The present invention also provides pharmaceutical compositions, and a kit comprising the RNA(s). Further, the invention also comprises medical uses of the RNA(s) and compositions comprising the RNA(s).

Abstract: The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGK?, DGK?, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof.

Abstract: The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross -linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi -conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency.

Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: The present invention relates to the use of transcriptional activators from prokaryotic organisms for use in eukaryotic cells, such as yeast as sensors of intracellular and extracellular accumulation of a ligand or metabolite specifically activating this transcriptional activator in a eukaryot, such as yeast cell, such as a cell engineered to produce this ligand. The transcriptional activator controls a promoter upstream of one or more gene, which may include e.g. a reporter gene that may be a fluorescence marker, such as luciferase, green fluorescent protein or a gnee encoding antibiotic resistance.

Abstract: A method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line comprising an expression construct comprising a regulatable promoter and a nucleic acid molecule encoding a POI under the transcriptional control of said promoter, comprising the steps a) cultivating the cell line with a basal carbon source repressing the promoter, b) cultivating the cell line with a limited amount of a supplemental carbon source de-repressing the promoter to induce production of the POI at a transcription rate of at least 15% as compared to the native pGAP promoter, and c) producing and recovering the POI; and further an isolated regulatable promoter and a respective expression system.

Abstract: The present invention relates generally to methods of molecular biology and gene silencing to control pests.

Abstract: The present disclosure relates generally to the identification of enzymes within the cyclopamine biosynthesis pathway as well as to engineering transgenic plants or organisms for the production of cyclopamine.

Abstract: There are provided plants of Papaver somniferum for the production of codeine, methods for providing the plants, and poppy straw, concentrate of poppy straw, latex, opium and codeine from the plants. The plants have codeine as the predominant alkaloid. Also disclosed are plants in which a stably inheritable high codeine chemotype trait is linked to a recessive trait for lighter leaf colour. Methods of producing such plants through the exposure of parent plant lines to mutagenizing agents are also disclosed.

Abstract: Methods are provided to mutate, in a targeted manner, the genome of a plant cell using a double stranded DNA break inducing enzyme. Also provided are plants, in particular Brassica plants that yield seeds producing oils having a reduced total saturated fatty acid content, and method for making such plants.

Abstract: The present invention relates, inter alia, to vegetative plant parts, such as from a Sorghum sp. and/or a Zea mays plant, which comprise a total fatty acid (TFA) content which comprises fatty acids esterified in the form of triacylglycerols (TAG) and fatty acids in the form of lipids other than TAG, wherein the vegetative plant parts comprise greatly increased levels of TFA, for example a TFA content of about 5% (w/w dry weight). The present invention also relates to the use of the vegetative plant parts as a feedstuff, and/or to produce a feedstuff, for animal consumption.

Abstract: The present invention relates to a genetic construct comprising a nucleic acid sequence encoding cytokinin biosynthetic isopentenyl-transferase enzyme (IPT) operable linked to a promoter allowing expression of said nucleic acid sequence in cambial cells. The invention relates also a method for producing a transgenic plant capable of increased biomass production and/or increased stem volume growth compared to wild type plant and a method for improving the production of biomass and/or increased stem volume growth in trees, as well as to a tree that over expresses an endogenous or exogenous nucleic acid sequence encoding IPT in cambial cells and a wood product obtainable from the transgenic tree.

Abstract: The invention relates to biotechnology and provides novel recombinant DNA molecules and engineered proteins for conferring tolerance to protoporphyrinogen oxidase-inhibitor herbicides. The invention also provides herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same.

Abstract: The invention provides plants comprising transgenic event MON 88302 that exhibit tolerance to glyphosate herbicide. The invention also provides seeds, plant parts, cells, commodity products, and methods related to the event. The invention also provides DNA molecules that are unique to the event and were created by the insertion of transgenic DNA into the genome of a Brassica napus plant.

Abstract: The present invention provides breeding methods and compositions to enhance the germplasm of a plant. The methods describe the identification and accumulation of transgenes and favorable haplotype genomic regions in the germplasm of a breeding population of crop plants.

Abstract: The present invention provides breeding methods and compositions to enhance the germplasm of a plant. The methods describe the identification and accumulation of transgenes and favorable haplotype genomic regions in the germplasm of a breeding population of crop plants.

Abstract: The disclosure provides polynucleotide molecules encoding novel defensins conferring increased pest tolerance and/or pesticidal activity when expressed in a plant, and recombinant DNA constructs and vectors comprising these molecules. Methods of making transgenic plants comprising recombinant defensin-encoding polynucleotide molecules and constructs, and transgenic plants, plant parts and seeds produced by these methods are provided. Compositions comprising one or more novel defensins of the disclosure are also provided having pesticidal and/or anti-microbial activity, as well as methods of their use.

Abstract: The present invention relates to the field of spinach breeding, in particular to a new dominant resistance gene, designated RPF12, which confers resistance against all races of Peronospora farinosa and to spinach plants comprising said gene.